The Asian Scientist 100
Lu Ke
Institution
Chinese Academy of Sciences
Country
China
Field
Materials Sciences
Lu is the winner of the 2020 Future Science Prize (Physical Science Prize) for discovering and synthesizing a superior nanotwinned structure and gradient nanostructure.
(Photo: Future Science Prize)
AWARDS
- Future Science Prize 2020
Related articles
Huahai, Oncobiologics Partner On Biosimilar Monoclonal Antibodies
Oncobiologics, Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd have agreed to jointly develop, manufacture, and commercialize biosimilar monoclonal antibody products.
Gene For Bones & Connective Tissue Disorders Identified
Researchers have identified a gene that when mutated is responsible for a spectrum of disorders affecting the bones and connective tissue.
Clinical Trial Uses South Pacific Plant Kava To Treat Anxiety
An Australian clinical study has shown that Kava, a medicinal South Pacific plant, significantly reduced the symptoms of people suffering from anxiety.
ScinoPharm, Coland Holdings To Co-Develop Generic Oncologic Drugs
ScinoPharm Taiwan Ltd. and Coland Holdings Ltd. announced this week a strategic alliance to develop a series of generic oncological drugs for Mainland China.
Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma
U.S. biotech Sagent Pharma will acquire the remaining 50 percent interest of the Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited joint venture.
A*STAR, Oxford Biodynamics Partner On Stem Cell Research
A*STAR and Oxford Biodynamics have agreed to collaborate on a project to identify epigenetic signatures in stem cells.
Printing Flexible Electronic Circuits On Paper
Scientists in China have developed a method to print flexible electronic circuits on paper using liquid metal ink.
Taiwan & Mexico Launch Astronomical Observation Project, TAOS-2
A collaboration between Taiwan and Mexico aims to build a new observatory in California that will study the Solar System beyond Neptune.
Glaxo & Taiwan’s NRPB Sign Clinical Trial Research Pact
Taiwan's National Research Program for Biopharmaceuticals signed yesterday an MOU with GlaxoSmithKline to develop Taiwan as a clinical trial hub in Asia.